
Personalized mRNA Melanoma Vaccine Cuts Recurrence Risk by 42%
In an international Phase III trial, adding the personalized therapeutic vaccine intismeran to pembrolizumab immunotherapy reduced the risk of recurrence or death by 42% in high-risk melanoma patients after surgery. Presented at the ESMO Congress 2026, the findings establish a new therapeutic approach combining tailored neoantigen targeting with immune checkpoint blockade. This medical innovation offers post-surgical protection for patients facing high chances of cancer relapse.
Giovanni Sapere
















